In 2019, the clinical approval study for Transcranial Pulse Stimulation (TPS) with STORZ MEDICAL’s NEUROLITH® system was published in the prestigious journal Advanced Science [1]. Prof. Dr. Beisteiner’s study, which was conducted at the Medical University of Vienna Beisteiner, documents the positive effects of TPS in the treatment of patients with Alzheimer’s dementia.
Uno studio di Matt et al. (Facoltà di Medicina di Vienna, Clinica universitaria di Neurologia), pubblicato nel gennaio 2022, analizza gli effetti a lungo termine della Stimolazione transcranica a impulsi (TPS) con il Sistema NEUROLITH® sul cervello umano e sul comportamento.1 Per la prima volta, lo studio randomizzato, in doppio cieco, controllato con dispositivo inattivo (sham), fornisce una prova sham-controllata degli effetti corrispondenti.
Un nuovo studio pubblicato a febbraio 2022 da Matt et al. (Facoltà di Medicina di Vienna, Clinica Universitaria di Neurologia) presenta una dettagliata sottoanalisi che, sulla base di dati neuropsicologici e di imaging funzionale, indaga i possibili effetti antidepressivi della stimolazione transcranica a impulsi (TPS) con il sistema NEUROLITH.2
The acoustic pulses generated by Transcranial Pulse Stimulation (TPS) have been used successfully in various medical fields (urology, orthopaedics, cardiology….) for decades under the term »extracorporeal shock wave therapy«.
Shock waves are similar to ultrasound. But there is a major difference:
The authors of a follow-up study (published in 2021) investigated the possible benefits of TPS treatment concerning brain morphology, namely the cortical atrophy characteristic of Alzheimer’s disease [1]. They found a significant correlation between neuropsychological improvement and cortical thickness increase in AD-critical brain areas.
Transcranial Pulse Stimulation (TPS) with the NEUROLITH® is increasingly gaining momentum: Since the CE approval for the »treatment of the central nervous system of patients with Alzheimer’s disease« in 2018, more than 50 NEUROLITH® systems have been installed worldwide. In June 2021, three more devices were installed in renowned neurological specialist clinics in Germany, Austria, and Turkey.
Transcranial Pulse Stimulation (TPS) with the NEUROLITH® system is a new therapy option for patients with Alzheimer’s disease that allows targeted stimulation of cerebral regions.
Key-facts:
One of the highlights of the new NEUROLITH® system is its innovative BodyTrack software – a unique tool for the visualization and control of the TPS pulses applied and of treatment progress. Real-time tracking of the handpiece position enables automatic visualization of the treated regions. The use of personalized MRI data allows specific characteristics of the patient’s brain to be taken into account.
»Overall, I feel good after the treatment and progress has been made. I notice that I respond well when someone talks to me and find the words to express myself better. In addition, my memory has improved somewhat. When I go shopping, I take the shopping list just to be on the safe side, although I could do without it.
Transcranial Pulse Stimulation (TPS) with the NEUROLITH® system is performed by a trained practitioner and is done on an outpatient basis. During treatment, the patient sits comfortably in a chair and can move freely at any time. To ensure optimal transmission of the pulses, the therapist applies ultrasound gel to the scalp or hair – it is not necessary to shave the patient’s head. The patient then puts on a pair of special glasses so that the position of the head can be detected.
